Anisimov Vladimir N, Ukraintseva Svetlana V, Anikin Ivan V, Popovich Irina G, Zabezhinski Mark A, Bertsein Lev M, Arutjunyan Alexander V, Ingram Donald K, Lane Mark A, Roth George S
N.N. Petrov Research Institute of Oncology, D.O. Ott Research Institute of Obstetrics and Gynecology, St. Petersburg, Russia.
Gerontology. 2005 Jan-Feb;51(1):19-28. doi: 10.1159/000081430.
Caloric restriction (CR) is the only treatment known to substantially prolong both average and maximal life span in experimental animals. Interventions that mimic certain effects of CR could be potential anti-aging treatments in humans. Drugs which reduce appetite (anorexiants) represent one class of candidate treatments. Agents that reduce the glucose utilization by the organism could also represent another class of candidate CR mimetics.
In our study, we addressed the following questions: (1) Does treatment with an anorexiant reduce caloric intake and body weight of experimental animals comparable to that caused by CR? (2) Does treatment with an antidiabetic agent influence caloric intake and body weight? (3) Does treatment with any of these drugs affect metabolic parameters of an organism in the way similar to that observed with CR?
One hundred and twenty 6-month-old female Wistar-derived LIO rats were randomly subdivided into four groups and exposed to: (1) ad libitum feeding with placebo (controls); (2) the antidiabetic drug phenformin (2 mg/kg); (3) the anorectic drug phentermine (1 mg/kg), and (4) the same amount of food as the group with the least food intake during the previous week (pair-fed controls). Food and water intake, body weight, and rectal temperature were measured weekly during 16 weeks. At the end of the 16th week of the experiment, serum levels of glucose, total beta-lipoprotein and pre-beta-lipoprotein fractions, cholesterol, triglycerides, insulin, total triiodothyronine, and free thyroxine were estimated. The contents of diene conjugates and Schiff's bases, total antioxidant activity, the activities of Cu/Zn superoxide dismutase, glutathione S-transferase, and glutathione peroxidase, and the generation of reactive oxygen species (ROS) were studied in brain and liver homogenates and in the serum.
The controls exposed to pair feeding had a significantly reduced food consumption (about 20%) as compared with the ad libitum fed controls and thus exhibited a moderate CR. Treatment with phentermine reduced the caloric intake by about 12% as compared with the ad libitum fed controls. Body weight and water intake in this group were only slightly decreased (by about 2 and 5%, respectively) as compared with the controls. The mean rectal temperature in the phentermine group (38 degrees C) was significantly higher than in the ad libitum fed (37.8 degrees C) and pair-fed (37.6 degrees C) controls. Treatment with phentermine also resulted in significantly reduced ROS levels in all tissues studied, while the highest ROS production was found in ad libitum (blood serum) and pair-fed (brain) controls. Treatment with phenformin did not significantly influence food and water consumption, body weight, and temperature when compared with the ad libitum fed controls. Rats treated with this antidiabetic drug showed intermediate values of ROS generation. Differences among the groups in total antioxidant activity were not obvious.
Treatment with phentermine reduces caloric intake slightly less than is commonly observed in CR studies. CR due to forcibly reduced feeding and CR due to substance-suppressed appetite appear to act through different metabolic mechanisms and thus may affect aging and longevity in different ways.
热量限制(CR)是已知的唯一能显著延长实验动物平均寿命和最大寿命的疗法。模拟CR某些效应的干预措施可能成为人类潜在的抗衰老疗法。减少食欲的药物(食欲抑制剂)是一类候选治疗药物。降低机体葡萄糖利用率的药物也可能是另一类CR模拟物。
在我们的研究中,我们探讨了以下问题:(1)使用食欲抑制剂治疗是否能像CR那样降低实验动物的热量摄入和体重?(2)使用抗糖尿病药物治疗是否会影响热量摄入和体重?(3)使用这些药物中的任何一种进行治疗是否会以与CR相似的方式影响机体的代谢参数?
将120只6个月大的雌性Wistar品系LIO大鼠随机分为四组,并给予以下处理:(1)自由摄食安慰剂(对照组);(2)抗糖尿病药物苯乙双胍(2毫克/千克);(3)食欲抑制药物芬特明(1毫克/千克),以及(4)与前一周食物摄入量最少的组相同量的食物(配对喂养对照组)。在16周内每周测量食物和水的摄入量、体重和直肠温度。在实验的第16周结束时,估计血清中的葡萄糖、总β-脂蛋白和前β-脂蛋白组分、胆固醇、甘油三酯、胰岛素、总三碘甲状腺原氨酸和游离甲状腺素水平。研究了脑和肝匀浆以及血清中双烯共轭物和席夫碱的含量、总抗氧化活性、铜/锌超氧化物歧化酶、谷胱甘肽S-转移酶和谷胱甘肽过氧化物酶的活性以及活性氧(ROS)的产生。
与自由摄食对照组相比,配对喂养的对照组食物消耗量显著降低(约20%),因此呈现出中度的CR。与自由摄食对照组相比,芬特明治疗使热量摄入降低了约12%。该组的体重和水摄入量与对照组相比仅略有下降(分别约为2%和5%)。芬特明组的平均直肠温度(38摄氏度)显著高于自由摄食组(37.8摄氏度)和配对喂养组(37.6摄氏度)的对照组。芬特明治疗还导致所有研究组织中的ROS水平显著降低,而自由摄食组(血清)和配对喂养组(脑)的对照组中ROS产生量最高。与自由摄食对照组相比,苯乙双胍治疗对食物和水的消耗量、体重和体温没有显著影响。用这种抗糖尿病药物治疗的大鼠ROS产生量处于中间值。各组之间的总抗氧化活性差异不明显。
芬特明治疗使热量摄入的降低幅度略小于CR研究中常见的幅度。因强制减少进食导致的CR和因物质抑制食欲导致的CR似乎通过不同的代谢机制起作用,因此可能以不同方式影响衰老和寿命。